keyword
MENU ▼
Read by QxMD icon Read
search

Enobosarm

keyword
https://www.readbyqxmd.com/read/27827563/analytical-strategies-to-detect-enobosarm-administration-in-bovines
#1
Nora Cesbron, Alexandre Sydor, Mylène Penot, Stéphanie Prevost, Bruno Le Bizec, Gaud Dervilly-Pinel
Selective androgen receptor modulators (SARMs) are a novel class of androgen receptor ligands. They are intended to exhibit the same kind of effects as androgenic drugs, like anabolic steroids, but be much more selective in their action, targeting particular tissues without any undesirable effects on others. While the main applications of these synthetic substances are for therapeutic purposes, they also have a high potential for misuse in veterinary practice and the sporting world. In order to guarantee the consumers with food from animal origin free from any residues of such compounds, analytical strategies are required to ensure safe food and also enable fair trade between producers...
November 9, 2016: Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment
https://www.readbyqxmd.com/read/27382931/novel-therapeutic-options-for-cachexia-and-sarcopenia
#2
Alessio Molfino, Maria Ida Amabile, Filippo Rossi Fanelli, Maurizio Muscaritoli
INTRODUCTION: Cachexia and sarcopenia are conditions phenotypically characterized by muscle loss and represent a factor of poor prognosis, increasing patients' morbidity and mortality. Cachectic and sarcopenic patients often suffer from low quality of life, presenting lower muscle strength and appetite loss, which makes research on novel treatment strategies to ameliorate clinical response including patient's symptoms, the objective of scientific interest. AREAS COVERED: This article covers recent developments in the area of cachexia and sarcopenia treatment and therapeutic interventions, targeting central nervous system involvement, key inflammatory and muscle-specific metabolic pathways...
October 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27138015/study-design-and-rationale-for-the-phase-3-clinical-development-program-of-enobosarm-a-selective-androgen-receptor-modulator-for-the-prevention-and-treatment-of-muscle-wasting-in-cancer-patients-power-trials
#3
REVIEW
Jeffrey Crawford, Carla M M Prado, Mary Ann Johnston, Richard J Gralla, Ryan P Taylor, Michael L Hancock, James T Dalton
Muscle wasting in cancer is a common and often occult condition that can occur prior to overt signs of weight loss and before a clinical diagnosis of cachexia can be made. Muscle wasting in cancer is an important and independent predictor of progressive functional impairment, decreased quality of life, and increased mortality. Although several therapeutic agents are currently in development for the treatment of muscle wasting or cachexia in cancer, the majority of these agents do not directly inhibit muscle loss...
June 2016: Current Oncology Reports
https://www.readbyqxmd.com/read/27105861/pharmacokinetic-drug-interactions-of-the-selective-androgen-receptor-modulator-gtx-024-enobosarm-with-itraconazole-rifampin-probenecid-celecoxib-and-rosuvastatin
#4
Christopher C Coss, Amanda Jones, James T Dalton
GTx-024 (also known as enobosarm) is a first in class selective androgen receptor modulator being developed for diverse indications in oncology. Preclinical studies of GTx-024 supported the evaluation of several potential drug-drug interactions in a clinical setting. A series of open-label Phase I GTx-024 drug-drug interaction studies were designed to interrogate potential interactions with CYP3A4 inhibitor (itraconazole), a CYP3A4 inducer (rifampin), a pan-UGT inhibitor (probenecid), a CYP2C9 substrate (celecoxib) and a BCRP substrate (rosuvastatin)...
August 2016: Investigational New Drugs
https://www.readbyqxmd.com/read/26990774/specific-characterization-of-non-steroidal-selective-androgen-peceptor-modulators-using-supercritical-fluid-chromatography-coupled-to-ion-mobility-mass-spectrometry-application-to-the-detection-of-enobosarm-in-bovine-urine
#5
Laure Beucher, Gaud Dervilly-Pinel, Nora Cesbron, Mylène Penot, Audrey Gicquiau, Fabrice Monteau, Bruno Le Bizec
Currently under development for therapeutic purposes in human medicine, non-steroidal selective androgen receptor modulators (non-steroidal SARMs) are also known to impact growth associated pathways. As such, they present a potential for abuse in sports and food-producing animals as interesting alternative anabolic substances. Forbidden since 2008 by the World Anti-Doping Agency (WADA) these compounds are however easily available and could be (mis)used in livestock production as growth promoters. To prevent such practices, dedicated analytical strategies have to be developed for specific and sensitive detection of these compounds in biological matrices...
March 16, 2016: Drug Testing and Analysis
https://www.readbyqxmd.com/read/26974316/clinical-results-in-cachexia-therapeutics
#6
Jeffrey Crawford
PURPOSE OF REVIEW: This article highlights recent developments in the area of cancer cachexia and therapeutic interventions. RECENT FINDINGS: Therapeutic interventions in cancer cachexia have been guided by clinical studies focused on the central role of muscle and the increased use of CT imaging to measure the impact of skeletal muscle loss on clinical outcomes. At the translational level, a number of different model systems have emphasized the importance of blockade of tumor-induced inflammation and its potential impact on reversing the cachexia phenotype, including FN14, a receptor in the TNF pathway, as well as the parathyroid hormone-related protein...
May 2016: Current Opinion in Clinical Nutrition and Metabolic Care
https://www.readbyqxmd.com/read/25804188/treatment-of-cachexia-an-overview-of-recent-developments
#7
REVIEW
Stephan von Haehling, Stefan D Anker
Body wasting in the context of chronic illness is associated with reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletal muscle mass and strength, exercise capacity, and survival in the context of cachexia and body wasting, many of them in patients with cancer. The aim of this article is to summarise clinical trials published over the last two years. Therapeutic approaches discussed here include appetite stimulants like megestrol acetate, l-carnitine, or melatonin, anti-inflammatory drugs like thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin, nutritional support, and anabolics like enobosarm and testosterone...
April 1, 2015: International Journal of Cardiology
https://www.readbyqxmd.com/read/25455531/treatment-of-cachexia-an-overview-of-recent-developments
#8
REVIEW
Stephan von Haehling, Stefan D Anker
Body wasting in the context of chronic illness is associated with reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletal muscle mass and strength, exercise capacity, and survival in the context of cachexia and body wasting, many of them in patients with cancer. The aim of this article was to summarize clinical trials published over the past 2 years. Therapeutic approaches discussed include appetite stimulants, such as megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs, such as thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin; nutritional support, and anabolics, such as enobosarm and testosterone...
December 2014: Journal of the American Medical Directors Association
https://www.readbyqxmd.com/read/24595460/highlights-from-the-7th-cachexia-conference-muscle-wasting-pathophysiological-detection-and-novel-treatment-strategies
#9
Nicole Ebner, Lisa Steinbeck, Wolfram Doehner, Stefan D Anker, Stephan von Haehling
This article highlights preclinical and clinical studies in the field of wasting disorders that were presented at the 7th Cachexia Conference held in Kobe, Japan, in December 2013. This year, the main topics were the development of new methods and new biomarkers in the field of cachexia and wasting disorders with particular focus on inflammatory pathways, growth differentiation factor-15, myostatin, the ubiquitin proteasome-dependent pathway, valosin and the regulation of ubiquitin-specific protease 19 that is involved in the differentiation of myogenin and myosin heavy chain...
March 2014: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/24490605/enobosarm-gtx-024-s-22-a-potential-treatment-for-cachexia
#10
Reshmi Srinath, Adrian Dobs
Muscle loss and wasting occurs with aging and in multiple disease states including cancer, heart failure, chronic obstructive pulmonary disease, end-stage liver disease, end-stage renal disease and HIV. Cachexia is defined as a multifactorial syndrome that is associated with anorexia, weight loss and increased catabolism, with increased morbidity and mortality. Currently no therapy is approved for the treatment or prevention of cachexia. Different treatment options have been suggested but many have proven to be ineffective or associated with adverse events...
February 2014: Future Oncology
https://www.readbyqxmd.com/read/24189892/selective-androgen-receptor-modulators-for-the-prevention-and-treatment-of-muscle-wasting-associated-with-cancer
#11
REVIEW
James T Dalton, Ryan P Taylor, Michael L Mohler, Mitchell S Steiner
PURPOSE OF REVIEW: This review highlights selective androgen receptor modulators (SARMs) as emerging agents in late-stage clinical development for the prevention and treatment of muscle wasting associated with cancer. RECENT FINDINGS: Muscle wasting, including a loss of skeletal muscle, is a cancer-related symptom that begins early in the progression of cancer and affects a patient's quality of life, ability to tolerate chemotherapy, and survival. SARMs increase muscle mass and improve physical function in healthy and diseased individuals, and potentially may provide a new therapy for muscle wasting and cancer cachexia...
December 2013: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/23515589/highlights-of-mechanistic-and-therapeutic-cachexia-and-sarcopenia-research-2010-to-2012-and-their-relevance-for-cardiology
#12
REVIEW
Markus S Anker, Stephan von Haehling, Jochen Springer, Maciej Banach, Stefan D Anker
Sarcopenia and cachexia are significant medical problems with a high disease-related burden in cardiovascular illness. Muscle wasting and weight loss are very frequent particularly in chronic heart failure and they relate to poor prognosis. Although clinically largely underestimated, the fields of cachexia and sarcopenia are of great relevance to cardiologists. In cachexia and sarcopenia a significant number of research publications related to basic science questions of muscle wasting and lipolysis were published between 2010 and 2012...
February 21, 2013: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/23499390/effects-of-enobosarm-on-muscle-wasting-and-physical-function-in-patients-with-cancer-a-double-blind-randomised-controlled-phase-2-trial
#13
RANDOMIZED CONTROLLED TRIAL
Adrian S Dobs, Ralph V Boccia, Christopher C Croot, Nashat Y Gabrail, James T Dalton, Michael L Hancock, Mary A Johnston, Mitchell S Steiner
BACKGROUND: Cancer-induced muscle wasting begins early in the course of a patient's malignant disease, resulting in declining physical function and other detrimental clinical consequences. This randomised, double-blind, placebo-controlled phase 2 trial assessed the efficacy and safety of enobosarm, a selective androgen receptor modulator, in patients with cancer. METHODS: We enrolled male (>45 years) and female (postmenopausal) patients with cancer who were not obese and who had at least 2% weight loss in the previous 6 months...
April 2013: Lancet Oncology
https://www.readbyqxmd.com/read/23174169/highlights-of-the-mechanistic-and-therapeutic-cachexia-and-sarcopenia-research-2010-to-2012-and-their-relevance-for-cardiology
#14
REVIEW
Markus S Anker, Stephan von Haehling, Jochen Springer, Maciej Banach, Stefan D Anker
Sarcopenia and cachexia are significant medical problems with a high disease related burden in cardiovascular illness. Muscle wasting and weight loss are very frequent particularly in chronic heart failure and they relate to poor prognosis. Although clinically largely underestimated, the fields of cachexia and sarcopenia are of great relevance to cardiologists. In cachexia and sarcopenia a significant number of research publications related to basic science questions of muscle wasting and lipolysis were published between 2010 and 2012...
January 10, 2013: International Journal of Cardiology
https://www.readbyqxmd.com/read/22031847/the-selective-androgen-receptor-modulator-gtx-024-enobosarm-improves-lean-body-mass-and-physical-function-in-healthy-elderly-men-and-postmenopausal-women-results-of-a-double-blind-placebo-controlled-phase-ii-trial
#15
James T Dalton, Kester G Barnette, Casey E Bohl, Michael L Hancock, Domingo Rodriguez, Shontelle T Dodson, Ronald A Morton, Mitchell S Steiner
BACKGROUND: Cachexia, also known as muscle wasting, is a complex metabolic condition characterized by loss of skeletal muscle and a decline in physical function. Muscle wasting is associated with cancer, sarcopenia, chronic obstructive pulmonary disease, end-stage renal disease, and other chronic conditions and results in significant morbidity and mortality. GTx-024 (enobosarm) is a nonsteroidal selective androgen receptor modulator (SARM) that has tissue-selective anabolic effects in muscle and bone, while sparing other androgenic tissue related to hair growth in women and prostate effects in men...
September 2011: Journal of Cachexia, Sarcopenia and Muscle
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"